

Evgen Pharma plc
("Evgen" or "the Company" or "the Group")

Evgen Notes First Closing of Series B Fund Raise by Partner, Stalicia SA

Alderley Park, UK - 16 January 2024: Evgen Pharma plc (AIM: EVG, Evgen), a clinical stage drug development company developing sulforaphane-based medicines, notes that Stalicia SA, its partner in autism spectrum disorder (ASD) and other neurodevelopmental disorders has announced that it has raised \$17.4m inclusive of a credit facility to support programmes on STP1 their first asset in Autism Spectrum Disorder (ASD) and a further asset in Substance Use Disorders (SUD) together with a biosampling and patient identification study in ASD.

Evgen continues to work with Stalicia on delivery of a milestone payment for SFX-01 (Stalicia's STP2). The companies are engaged in analysis and interpretation of Evgen's recent Phase 1b healthy volunteer PK/PD study and the implications for a future Phase 2 trial in ASD. The Company will provide updates on the status of the programme in due course and has not anticipated any milestone payments from Stalicia in its financial forecasting.

Dr Huw Jones, Evgen CEO commented:

"We extend our congratulations to Stalicia on this round of financing and look forward to continuing discussions on SFX-01 in ASD. In the meantime we continue to advance our internal programme in glioblastoma with the Erasmus medical centre in Rotterdam, NL and our pre-clinical programmes in rhabdomyosarcoma, glioblastoma, bowel cancer and breast cancer with our leading academic collaborators."

-Ends-

Enquiries:

Evgen Pharma plc
Dr Huw Jones, CEO
Toni Hänninen, CFO
Dr Helen Kuhlman, CBO

[+44 1625 466591](tel:+441625466591)

Cavendish (Nominated Advisor and Broker)
Geoff Nash / Teddy Whiley (Corporate Finance)
Nigel Birks (ECM)

[+44 20 7220 0500](tel:+442072200500)

Instinctif Partners
Melanie Toyne-Sewell / Jack Kincade

[+44 207 457 2020](tel:+442074572020)
evgen@instinctif.com

About Evgen Pharma plc

Evgen Pharma is a clinical stage drug development company developing sulforaphane based medicines for the treatment of multiple diseases. The Company's core technology is Sulforadex®, a method for synthesising and stabilising the highly biologically active compound sulforaphane and novel proprietary analogues based on sulforaphane.

The Company's lead asset, SFX-01, is a patented composition of synthetic sulforaphane and alpha-cyclodextrin and has undergone clinical trials for oestrogen-positive (ER+) metastatic breast cancer and recently a Phase 1b study of the Company's new enteric coated tablet formulation. The FDA has granted Orphan Drug status to SFX-01 in malignant glioma. SFX-01 will be investigated initially in this indication as an investigator sponsored study in the Netherlands supported by a substantial non-dilutive grant.

The Company also has a wide number of collaborations with leading academic centres in the UK, Europe and the US as part of the continuing strategy to build the scientific data for the compound. Recently, Evgen completed an out-licensing transaction with Stalicia SA, a Swiss specialist company in neurodevelopmental disorders, commencing with autism spectrum disorder. The deal, if successful, will generate milestone payments of \$160.5m and a double-digit royalty on sales.

The Company has its headquarters and registered office at Alderley Park, Cheshire. It is listed on AIM in London and trades under the ticker symbol EVG.

For further information, please visit: www.evgen.com.

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact ms@lseg.com or visit www.ms.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

NRAEASFKFESLEFA

